Prof. Michel S. Bourin

1. Bourin, M. (2024). Neurobiology of Addiction. In Psychiatry and Neuroscience Update–Vol. V: Addiction: From Laboratory and Anthropology to Clinical Practice (pp. 171-180). Cham: Springer Nature Switzerland.
2. Ballaz, S., & Bourin, M. (2023). Anti-inflammatory therapy as a promising target in neuropsychiatric disorders. Neuroinflammation, Gut-Brain Axis and Immunity in Neuropsychiatric Disorders, 459-486.
3. Bourin, M. (2023). Drug therapy for bipolar disorder: A review of efficacy evidence. Archives of Drug therapy for bipolar disorder: A review of efficacy evidence and Anxiety, 9(2), 079-088.
4. Ballaz, S., Espinosa, N., & Bourin, M. (2021). Does endogenous cholecystokinin modulate alcohol intake?. Neuropharmacology, 193, 108539.
5. Ballaz, S. J., & Bourin, M. (2021). Cholecystokinin-mediated neuromodulation of anxiety and schizophrenia: a “dimmer-switch” hypothesis. Current Neuropharmacology, 19(7), 925-938.
6. Ballaz, S. J., Bourin, M., Akil, H., & Watson, S. J. (2020). Blockade of the cholecystokinin CCK-2 receptor prevents the normalization of anxiety levels in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 96, 109761.
7. Nuss, P., Ferreri, F., & Bourin, M. (2019). An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. Neuropsychiatric Disease and Treatment, 1781-1795.
8. Bourin, M. (2019). The test retest model of anxiety: An appraisal of findings to explain benzodiazepine tolerance. Pharmacology Biochemistry and Behavior, 178, 39-41.
9. Songtachalert, T., Roomruangwong, C., Carvalho, A. F., Bourin, M., & Maes, M. (2018). Anxiety disorders: sex differences in serotonin and tryptophan metabolism. Current topics in medicinal chemistry, 18(19), 1704-1715.
10. Bandelow, B., Baldwin, D., Abelli, M., Bolea-Alamanac, B., Bourin, M., Chamberlain, S. R., ... & Riederer, P. (2017). Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. The World Journal of Biological Psychiatry, 18(3), 162-214.
11. Yatham, L. N., Vieta, E., Goodwin, G. M., Bourin, M., de Bodinat, C., Laredo, J., & Calabrese, J. (2016). Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. The British Journal of Psychiatry, 208(1), 78-86.
12. NUTT D., DEMYTTENAERE K., ZOLTAN J., AARE T., BOURIN M., CANONICO P.L., CARRASCO J.L., STAHL S.M. The other face of depression, reduced positive effect: the role of catecholamine in causation and cure. J. Psychopharmacology 2007, 5, 461-471.
13. BOURIN M., PRICA C. The role of mood stabilizers in treatment of the depressive facet of bipolar disorders. Neurosciences and Biobehavioral Reviews 2007, 31, 963-975.
14. PETIT-DEMOULIERE B., COGREL N., BOURIN M. Temporal parameters of one-trial tolerance to benzodiazepines in four-plate test retest. Behav. Br. Res, 2007, 183, 222-225.
15. BERK M., DODD S., KAVER-SANTANNA M., MAHLI G.S., BOURIN M., KAPCZINSRI F., NORMAN T. Dopamine dysregulation syndrome implication for a dopamine hypothesis of Bipolar disorder. Acta Psychiatr. Scand. (suppl.) 2007, 434, 41-49.
16. BOURIN M Traitement de la manie aigüe. Société de Neuropsychiatrie de l’Ouest. 2007, 135 ,36-49
17. PETIT-DEMOULIERE B., HASCOËT M., BOURIN M. Triggering factors for one-trial tolerance in the four-plate test-retest in mice. Eur. Neuropsychopharmacol .2008, 18, 41-47
18. MASSE F., PETIT-DEMOULIERE B., DUBOIS I., HASCOËT M., BOURIN M. Anxiolytic-like effects of DOI micro-inections into the hippocampus (but not the amygdala nort the PAG) in the mice four plates test. Beh. Brain Res. 2008, 188, 291-297.
19. DAILLY E., BOURIN M. The use of benzodiazepines in aged patients: clinical and pharmacological considerations. Pak. J. Pharm. Sci. 2008, 21, 89-95.
20. PRICA C., BOURIN M. Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression. Beh. Brain Res. 2008, 191, 49-54.
21. BOURIN M., PRICA C. Treatment of acute mania in bipolar disorder. Romanian Journal of Psychopharmacology, 2007, 7, 1-13.
22. PRICA C, HASCOËT M, BOURIN M. Is co-administration of bupropion with SSRIs andSNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? Behav Brain Res. 2008,194:92-99.
23. CHENU F., DAVID DJP, LEROUX-NICOLLET I, LE MAITRE E., GARDIER A.M., BOURIN M. 5-HT1B heteroreceptor activation induces an antidepressant-like effect with an alteration of serotonergic systems. Journal of Psychiatry and Neurosciences 2008, 38, 541-550.
24. BOURIN M. Mechanism of action and clinical feature of SNRIs: Venlafaxine and Minalcipran. Romanian Journal of Psychopharmacology 2008, 4 (on line).
25. BOURIN M., PRICA C. Recent drugs developed in unipolar depression. Romanian Journal of Psychopharmacology 2008, 4 (on line).
26. BOURIN M., PRICA C. Melatonin Receptor Agonist Agomelatine: A new drug for treating unipolar depression. Current Pharmaceutical Design 2009, 15, 1675-1682.
27. BANTSIELE G.B., BENTUE-FERRER D., SAÏKALI S., LAVIOLLE B., BOURIN M., REYMANN J.M. Behavioral effects of four antidepressants on an ischemic rat model of emotional disturbances. Beh. Brain Res. 2009. 201, 265–271.
28. 508- BOURIN MDrug assessment in the treatment of acute mania in bipolar disorder. Romanian Journal of Psychopharmacology 2009, 1 (on line).
29. PETIT-DEMOULIERE B., MASSE F.,COGREL N., HASOËT M., BOURIN M. Brain structures implicated in the four-plate test in naîve and experienced Swiss mice using injection of diazepam and the 5-HT2A agonist DOI. Beh. Brain Res.2009. 204 , 200–205.
30. BOURIN M., CHENU F., HASCOËT M. Topiramate and phenytoin anti-immobility effect in the mice forced swimming test is reversed by veratrine: Implication for bipolar depression treatment. Behav Brain Res. 2009 . 205, 421–425.
31. BOURIN M., CHENU F., PRICA C., HASCOËT M. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology2009 .206: 97-107.
32. BOURIN M., CHENU F., HASCOËT M. The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers. Curr Drug Targets. 2009. 10:1052-1060.